Abstract

BackgroundCalcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide whose biological activity has potential therapeutic value for many vascular related diseases. CGRP is a 37 amino acid neuropeptide that signals through a G protein-coupled receptor belonging to the secretin receptor family. Previous studies on the calcitonin-like receptor (CLR), which requires co-expression of the receptor-activity-modifying protein-1 (RAMP1) to function as a CGRP receptor, have shown an 18 amino acid N-terminus sequence important for binding CGRP. Moreover, several investigations have recognized the C-terminal amidated phenylalanine (F37) of CGRP as essential for docking to the mature receptor. Therefore, we hypothesize that hydrophobic amino acids within the previously characterized 18 amino acid CLR N-terminus domain are important binding contacts for the C-terminal phenylalaninamide of CGRP.ResultsTwo leucine residues within this previously characterized CLR N-terminus domain, when mutated to alanine and expressed on HEK293T cells stably transfected with RAMP1, demonstrated a significantly decreased binding affinity for CGRP compared to wild type receptor. Additional decreases in binding affinity for CGRP were not found when both leucine mutations were expressed in the same CLR construct. Decreased binding characteristic of these leucine mutant receptors was observed for all CGRP ligands tested that contained the necessary amidated phenylalanine at their C-terminus. However, there was no difference in the potency of CGRP to increase cAMP production by these leucine mutant receptors when compared to wild type CLR, consistent with the notion that the neuropeptide C-terminal F37 is important for docking but not activation of the receptor. This observation was conserved when modified CGRP ligands lacking the amidated F37 demonstrated similar potencies to generate cAMP at both wild type and mutant CLRs. Furthermore, these modified CGRP ligands displayed a significant but similar loss of binding for all leucine mutant and wild type CLR because the important receptor contact on the neuropeptide was missing in all experimental situations.ConclusionThese results are consistent with previous structure-function investigations of the neuropeptide and are the first to propose specific CLR binding contacts for the amidated F37 of CGRP that are important for docking but not activation of the mature CGRP receptor.

Highlights

  • Calcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide whose biological activity has potential therapeutic value for many vascular related diseases

  • Crude membrane preparations from these transfected HEK293T-receptoractivity-modifying protein-1 (RAMP1) cells were used in saturation binding experiments with increasing concentrations of [125I-Tyr]CGRP(8–37) in the absence or presence of Increasing concentrations of CGRP or the N-terminally acetylated peptide fragment, AcCGRP(19–37) were used to inhibit specific [125I-Tyr]CGRP(8–37) binding to membranes prepared from HEK293T-RAMP1 cells transiently transfected with wild type or mutant calcitonin-like receptor (CLR)

  • Specific [125ITyr]CGRP(8–37) binding was plotted versus increasing concentrations of the endogenous or modified neuropeptide and a competition curve for each membrane preparation was generated using non-linear regression analysis (Fig 3)

Read more

Summary

Introduction

Calcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide whose biological activity has potential therapeutic value for many vascular related diseases. The amidated C-terminal phenylalanine at position 37 of CGRP has been shown to be necessary for receptor interaction since deletion of this peptide residue or loss of the C-terminal amine results in a significant deficiency of high affinity binding [14,15]. This affinity loss of des-F37CGRP for the native receptor when compared to the endogenous neuropeptide is not due to disruption of the ligand structure [16]. There is no information in the literature regarding specific interactions of the receptor with these identified ligand domains, the C-terminus phenylalaninamide of CGRP

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call